![Elisabetta Bonzano: Internal Mammary Lymphadenopathy in Patients Treated with Neoadjuvant Chemotherapy](https://oncodaily.com/pub/uploads/2024/07/gettyimages-536228408-612x612-1.png)
Jul 16, 2024, 16:22
Elisabetta Bonzano: Internal Mammary Lymphadenopathy in Patients Treated with Neoadjuvant Chemotherapy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:
“Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial Annals of Surgical Oncology
With a median follow up of 3.72 years (range 0.4-10.2), there was no difference between IM+ versus IM- in
LRR (5.6% vs. 3.8%; p = 0.25),
DR (9.1% vs. 7.9%; p = 0.58),
or EFS (61.6% vs. 57.2%; p = 0.48).
This was true for patients with and without pCR.”
Read further.
Source: Elisabetta Bonzano/X
Aug 24, 2024, 06:55
Aug 24, 2024, 06:23
Aug 24, 2024, 05:36
Aug 23, 2024, 21:33